Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies-Reference-Cited by-同舟云学术

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

Published:2007-12 Issue:9603 Volume:370 Page:1907-1914
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Krishna Rajesh,Anderson Matt S,Bergman Arthur J,Jin Bo,Fallon Marissa,Cote Josee,Rosko Kim,Chavez-Eng Cynthia,Lutz Ryan,Bloomfield Daniel M,Gutierrez Maria,Doherty James,Bieberdorf Fredrick,Chodakewitz Jeffrey,Gottesdiener Keith M,Wagner John A

Publisher

Elsevier BV

Subject

General Medicine

Reference37 articles.

1. Pharmacotherapy for dyslipidaemia—current therapies and future agents;Bays;Expert Opin Pharmacother,2003

2. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis;Barter;Arterioscl Thromb Vasc Biol,2003

3. Plasma cholesteryl ester transfer protein;Tall;J Lipid Res,1993

4. Purification and characterization of a human plasma cholesteryl ester transfer protein;Hesler;J Biol Chem,1987

5. Identification and characterization of MK-0859, a novel cholesteryl ester transfer protein inhibitor;O'Neill,2007

Cited by 265 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia;Molecular Neurodegeneration;2023-11-16

2. Structural insights on the deformations induced by various mutations on cholesteryl ester transfer protein;Biophysical Chemistry;2023-10

3. Genetics of Cholesterol-Related Genes in Metabolic Syndrome: A Review of Current Evidence;Biomedicines;2022-12-13

4. Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels;International Journal of Molecular Sciences;2022-08-20

5. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?;Cardiovascular Research;2021-11-26